Brief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Yesterday 13:34
BRIEF-Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients Nov 12 (Reuters) - Astellas Pharma Inc. 4503.T:
IMMUNEERING TO COLLABORATE WITH ASTELLAS ON CLINICAL STUDIES OF INVESTIGATIONAL CLDN18.2 PROGRAMS IN COMBINATION WITH ATEBIMETINIB FOR PANCREATIC CANCER PATIENTS
Source text: ID:nGNXb47cNd
Further company coverage: 4503.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)